Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 3, 2009, Pages 239-260

  Krippendorff, Ben Fillippo ^a,b   Kuester, Katharina ^c,d   Kloft, Charlotte ^c,d   Huisinga, Wilhelm ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b INTERNATIONAL MAX PLANCK RESEARCH SCHOOL FOR COMPUTATIONAL BIOLOGY AND SCIENTIFIC COMPUTING   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antibodies; Biopharmaceuticals; Epidermal growth factor receptor; Michaelis Menten; Nonlinear dispostition; Nonlinear pharmacokinetics; Recepter mediated endocytosis; Receptor trafficking; Therapeutic proteins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CELL MEMBRANE; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG RECEPTOR BINDING; ENDOCYTOSIS; EXTRACELLULAR SPACE; INTERNALIZATION; MICHAELIS MENTEN KINETICS; NONLINEAR SYSTEM; PRIORITY JOURNAL;

ENDOCYTOSIS; MEMBRANE PROTEINS; NONLINEAR DYNAMICS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 67651155752     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9120-1     Document Type: Article

References (39)

1. Meibohm B (2006) Pharmacokinetics and pharmacodynamics of biotech drugs. Wiley-VCH Verlag, Weinheim
2. Kuester K, Kloft C (2006) Pharmacokinetics of monoclonal antibodies. In Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs, chapter 3. Wiley-VCH Verlag, Weinheim, pp 45-91
3. I Mahmood MD Green 2005 Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins Clin Pharmacokinet 44 331 347 (Pubitemid 40663681)
4. GJ Russell-Jones 2001 The potential use of receptor-mediated endocytosis for oral drug delivery Adv Drug Deliver Rev 46 59 73
5. A Sorkin M Von Zastrow 2002 Signal transduction and endocytosis: close encounters of many kinds Nat Rev Mol Cell Biol 3 600 614 (Pubitemid 34886971)
6. L Tang A Persky G Hochhaus B Meibohm 2004 Pharmacokinetic aspects of biotechnology products J Pharm Sci 93 2184 2204 (Pubitemid 39129617)
7. NL Dirks A Nolting A Kovar B Meibohm 2008 Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck J Clin Pharmacol 48 267 278 (Pubitemid 351257778)
8. K Kuester A Kovar C Lüpfert B Brockhaus C Kloft 2008 Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development Br J Cancer 98 900 906 (Pubitemid 351341615)
9. DR Mould KRD Sweeney 2007 The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development Curr Opin Drug Discov Dev 10 84 96 (Pubitemid 46438261)
10. C Kloft E-U Graefe P Tanswell AM Scott R Hofheinz A Amelsberg MO Karlsson 2004 Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients Invest New Drugs 22 39 52 (Pubitemid 38196981)
11. JJ Lammertsvan Bueren WK Bleeker HO Bøgh M Houtkamp J Schuurman JGJ van de Winkel PWHI Parren 2006 Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action Cancer Res 66 7630 7638 (Pubitemid 44289220)
12. EI Ette PJ Williams Y Ho Kim JR Lane M-J Liu EV Capparelli 2003 Model appropriateness and population pharmacokinetic modeling J Clin Pharmacol 43 610 623 (Pubitemid 36613120)
13. LB Sheiner SL Beal 1983 Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data J Pharmacokinet Biopharm 11 303 319 (Pubitemid 14074006)
14. BL Sheiner SL Beal 1981 Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data J Pharmacokinet Biopharm 9 635 651 (Pubitemid 12210179)
15. LB Sheiner SL Beal 1980 Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data J Pharmacokinet Biopharm 8 553 571 (Pubitemid 11097017)
16. DE Mager W Krzyzanski 2005 Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition Pharm Res 22 1589 1596 (Pubitemid 41355898)
17. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 507 532 (Pubitemid 34289541)
18. DE Mager 2006 Target-mediated drug disposition and dynamics Biochem Pharmacol 72 1 10 (Pubitemid 43795346)
19. ED Lobo RJ Hansen JP Balthasar 2004 Antibody pharmacokinetics and pharmacodynamics J Pharm Sci 93 2645 2668 (Pubitemid 39506617)
20. BS Hendriks G Orr A Wells HS Wiley DA Lauffenburger 2005 Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells J Biol Chem 280 6157 6169 (Pubitemid 40280101)
21. HS Wiley SY Shvartsman DA Lauffenburger 2003 Computational modeling of the EGF-receptor system: a paradigm for systems biology Trends Cell Biol 13 43 50 (Pubitemid 35453894)
22. CA Sarkar DA Lauffenburger 2003 Cell-level pharmacokinetic models of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo Mol Pharmacol 63 147 158 (Pubitemid 36043818)
23. A De Luca A Carotenuto A Rachiglio M Gallo MR Maiello D Aldinucci A Pinto N Normanno 2008 The role of the EGFR signaling in tumor microenvironment J Cell Physiol 214 559 567 (Pubitemid 351224199)
24. T Watanabe A Shintani M Nakata Y Shing J Folkman K Igarashi R Sasada 1994 Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction J Biol Chem 269 9966 9973
25. A Wells 1999 EGF receptor Int J Biochem Cell Biol 31 637 643 (Pubitemid 29248872)
26. PM Harari 2004 Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 689 708 (Pubitemid 40065545)
27. HS Wiley DD Cunningham 1981 A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands Cell 25 433 440 (Pubitemid 11046834)
28. H Shankaran H Resat HS Wiley 2007 Cell surface receptors for signal transduction and ligand transport: a design principles study PLoS Comput Biol 3 e101
29. J Baselga 2001 The EGFR as a target for anticancer therapy-focus on cetuximab Eur J Cancer 37 Suppl 4 S16 S22
30. J Baselga 2002 Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 Suppl 4 2 8 (Pubitemid 34977157)
31. J Baselga 2000 New therapeutic agents targeting the epidermal growth factor receptor J Clin Oncol 18 54S 59S (Pubitemid 30813112)
32. S Goel S Mani R Perez-Soler 2002 Tyrosine kinase inhibitors: a clinical perspective Curr Oncol Report 4 9 19
33. E Raymond S Faivre JP Armand 2000 Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 1 15 23 discussion 41-2 (Pubitemid 30828934)
34. BS Hendriks LK Opresko HS Wiley DA Lauffenburger 2003 Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects Cancer Res 63 1130 1137 (Pubitemid 36278448)
35. WK Bleeker JJ Lammertsvan Bueren HH van Ojik AF Gerritsen M Pluyter M Houtkamp E Halk J Goldstein J Schuurman MA van Dijk JGJ van de Winkel PWHI Parren 2004 Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy J Immunol 173 4699 4707 (Pubitemid 39280705)
36. L Bastholt L Specht K Jensen E Brun A Loft J Petersen H Kastberg JG Eriksen 2007 Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck Radiother Oncol 85 24 28 (Pubitemid 47562580)
37. A Wells JB Welsh CS Lazar H Steven Wiley GN Gill MG Rosenfeld 1990 Ligand-induced transformation by a noninternalizing epidermal growth factor receptor Science 247 962 964
38. CC Reddy A Wells DA Lauffenburger 1994 Proliferative response of fibroblasts expressing internalization-deficient epidermal growth factor (EGF) receptors is altered via differential EGF depletion effect Biotechnol Prog 10 377 384 (Pubitemid 2129380)
39. Godfrey K (1983) Compartmental models and their application. Academic Press, London